Order Article Reprints

Basoulis D, Mastrogianni E, Karamanakos G, Gkoufa A, Georgakopoulou VE, Makrodimitri S, Gamaletsou MN, Markogiannakis A, Sipsas NV. Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study. Viruses. 2024; 16(8):1345. https://doi.org/10.3390/v16081345

Basoulis, Dimitrios, Elpida Mastrogianni, Georgios Karamanakos, Aikaterini Gkoufa, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Maria N. Gamaletsou, Antonios Markogiannakis, and Nikolaos V. Sipsas. 2024. "Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study" Viruses 16, no. 8: 1345. https://doi.org/10.3390/v16081345

Basoulis, D., Mastrogianni, E., Karamanakos, G., Gkoufa, A., Georgakopoulou, V. E., Makrodimitri, S., Gamaletsou, M. N., Markogiannakis, A., & Sipsas, N. V. (2024). Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study. Viruses, 16(8), 1345. https://doi.org/10.3390/v16081345